3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Liquidia and its subsidiary Liquidia Technologies signed a settlement agreement with United Therapeutics on October 13, 2026, resolving all pending litigation between the companies. Liquidia will keep marketing YUTREPIA for pulmonary arterial hypertension but must remove the PH-ILD indication from the label and stop promoting it for that use, and it must make payments totaling a stated net $380.7 million in 2026 and 2027.
Net payment to United Therapeutics of $175.0 million due within 30 business days, plus $145.4 million in two $72.7 million installments due January 31, 2027 and April 30, 2027
Separate settlements with Sandoz, Henderson and PBM total about $60.3 million; the PBM agreement is with a related party that is controlled by a director, and the board's disinterested members approved it
Lender consent for a letter of credit tied to the settlement raised the minimum cash covenant under the revenue interest financing agreement from $15.0 million to $45.0 million
Preliminary, unaudited third-quarter 2026 YUTREPIA net product sales were $222.7 million, and cash and cash equivalents were $396.1 million as of September 30, 2026
Nasdaq's Hearings Panel decided on October 7, 2026, that CN Healthy Food Tech Group is in compliance and may remain listed, subject to conditions. The panel found the company failed to give Nasdaq and investors accurate information about its China Securities Regulatory Commission application, though it said the omission did not relate to finances or business operations.
Panel decision dated October 7, 2026; company may remain listed on Nasdaq
Company must keep remedial measures for three years from the panel decision date
One-year Discretionary Panel Monitor: any listing standard failure leads to a Staff Delisting Determination without a cure period
Company does not intend to seek Listing Council review; the council may still review on its own within 45 days
Eureka Acquisition Corp received a letter from Nasdaq on October 6, 2026, stating that it has regained compliance with the 300 public holders requirement for continued listing on the Nasdaq Capital Market, and the matter is now closed. The filing is administrative and confirms the company's continued Nasdaq listing status on this requirement.
Nasdaq letter dated October 6, 2026 confirmed regained compliance
Requirement: minimum 300 public holders under Nasdaq Listing Rule 5550(a)(3)
Nasdaq Listing Rule matter is now closed
Filing signed by CEO Fen Zhang on October 13, 2026
Equus Total Return, Inc. was notified by the NYSE on October 6, 2026, that its common stock fell below the $1.00 minimum average closing price over 30 consecutive trading days. The notice is a deficiency notice, not a delisting, and the stock continues to trade on the NYSE for now. Shareholders should note the company plans to cure the deficiency within a six-month period, with a reverse stock split among the options it is considering.
NYSE notice dated October 6, 2026 cites Section 802.01C: average closing price below $1.00 over 30 consecutive trading days
Company plans to notify the NYSE by October 20, 2026 of its intent to cure the deficiency
Cure period is six months from receipt of the notice; a reverse stock split is among the alternatives under consideration
Common stock continues to trade on the NYSE; the company said the notice does not affect its operations or SEC reporting
Park Dental Partners disclosed that unauthorized access to its network in August 2026 led to data being acquired, including patients' protected health information, and it is completing notifications under state and federal law. Four putative class actions have been filed in Minnesota state court, and the company says it has not identified any material impact on its financial condition or results to date.
Unauthorized network access identified on August 28, 2026; law enforcement notified
Four putative class actions filed in Ramsey County, Minnesota; first filed September 3, 2026
Plaintiffs moved on October 7, 2026 to consolidate the actions and appoint interim lead class counsel
No material impact on financial condition or results identified to date, including expected legal and advisor costs
SS Innovations said it submitted its response to an FDA request for additional information on its 510(k) application for the SSi Mantra surgical robotic system on October 5, 2026. The response includes final data from an expanded human clinical and human factors validation study and a bridging study, and the company expects the FDA to complete its review in the first quarter of 2027. The filing describes a regulatory milestone toward U.S. market entry but gives no financial results or timing guarantees.
Response to the FDA's request for additional information was submitted on October 5, 2026.
The response includes final data from an expanded human clinical and human factors validation study and a bridging study completed in August 2026 at Hospital Internacional de Colombia in Bucaramanga.
The company expects the FDA to complete its review of the response and the 510(k) submission in the first quarter of 2027.
The 510(k) submission covers the initial indication of cholecystectomy (gallbladder removal).
Eightco Holdings Inc. received a Nasdaq notice on October 8, 2026 stating it regained compliance with the $1.00 minimum bid price rule, after its stock closed at or above $1.00 for 10 consecutive business days from September 24 to October 7, 2026. Nasdaq closed the matter, and the notice has no effect on the listing or trading of the stock under the symbol ORBS.
Nasdaq notice dated October 8, 2026 confirms compliance with Listing Rule 5550(a)(2)
Closing bid price at or above $1.00 for 10 consecutive business days, September 24 to October 7, 2026
Earlier bid price deficiency notice was received August 5, 2026; compliance period was until February 1, 2027
Stock continues to trade on The Nasdaq Capital Market under ORBS
Newton Golf Company received a Nasdaq Staff determination on October 6, 2026, that it has not shown compliance with the $2,500,000 minimum stockholders' equity requirement for continued listing. Unless the company requests an appeal by October 13, 2026, its common stock will be suspended at the opening of business on October 15, 2026, and delisted from Nasdaq.
Nasdaq Staff determination dated October 6, 2026 cites the $2,500,000 stockholders' equity minimum under Listing Rule 5550(b)(1)
Appeal request deadline is October 13, 2026; without it, trading suspension begins October 15, 2026
Company intends to request a hearing before a Nasdaq Hearings Panel, which would stay the suspension and delisting pending the Panel's decision
The filing states there is no assurance the Panel will grant continued listing
On October 9, 2026, a federal court temporarily barred Corteva and EIDP from paying dividends or repurchasing shares, and from disposing of assets outside the ordinary course of business, in litigation filed by 15 states and one sovereign over the Corteva and Vylor separation. On October 10 the court stayed the order at the companies' request, and the companies have appealed to the Seventh Circuit, where the motion for a stay pending appeal remains pending. Shareholders face uncertainty over dividends and buybacks while the appeal is pending, and the filing states the separation itself was not affected.
Litigation commenced October 1, 2026 in the U.S. District Court for the Southern District of Indiana by 15 states and one sovereign
Temporary restraining order issued October 9, 2026 would have barred dividends and share repurchases absent a court order
On October 10, 2026 the court stayed the order; the companies filed an appeal and motion with the Seventh Circuit, both still pending
The separation of Corteva and Vylor was completed October 1, 2026, and the filing says the order does not affect it
ClearOne received a Nasdaq Staff determination on October 8, 2026 that it had not met the $2,500,000 minimum stockholders' equity requirement and will be delisted from The Nasdaq Capital Market. The company plans to request a hearing before a Nasdaq Hearings Panel by October 15, 2026, which would automatically stay the delisting, but trading is set to be suspended October 19, 2026 if no hearing is requested.
Nasdaq Staff determination letter received October 8, 2026
Stockholders' equity below the $2,500,000 minimum under Nasdaq Listing Rule 5550(b)(1)
Company intends to request a Panel hearing by October 15, 2026; trading suspension at the opening of business October 19, 2026 if not timely requested
Nasdaq compliance exception ran until October 5, 2026; the company says there is no assurance it will regain compliance or keep its listing
BridgeBio announced the FDA accepted its New Drug Application for oral infigratinib for children with achondroplasia with Priority Review, setting a PDUFA target action date of February 4, 2027. The company says the drug met its Phase 3 PROPEL 3 primary endpoint, but the filing does not describe financial results or a financial effect, so the update is mainly a regulatory milestone for shareholders.
FDA accepted the NDA with Priority Review; PDUFA target action date is February 4, 2027
PROPEL 3 met its primary endpoint: LS mean treatment difference of +1.74 cm/year and mean treatment difference of +2.10 cm/year in annualized height velocity (p<0.0001)
Oral infigratinib has Breakthrough Therapy Designation; BridgeBio plans to submit a Marketing Authorization Application to the EMA in Q4 2026
Approval is not assured; the filing notes the FDA may not approve the drug on the anticipated timeline or at all
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.